BioPharma Credit (LSE: BPCR)

Currency in USD

Last close As at 25/01/2023


−0.01 (−1.04%)

Market capitalisation


BioPharma Credit was incorporated in the UK in October 2016 and aims to generate predictable income for shareholders over the long term through a diversified portfolio of loans and other instruments backed by royalties or other cash flows derived from sales of approved life sciences products. This includes senior secured notes, royalty debt instruments and priority royalty tranches.

Latest Insights

View More

Investment Companies

BioPharma Credit – executive interview

Investment Companies

Biopharma Credit — New transaction of up to US$50m

Investment Companies

Biopharma Credit — Fully invested after recent transactions

Equity Analyst

Milosz Papst

Milosz Papst

Director, Financials

Key Management

  • Alexander Perfall

    VP, Investor Relations & Public Affairs

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 0.2 2.6 (2.8)
Relative (3.7) (7.8) (6.3)
52 week high/low US$1.0/US$0.9


BioPharma Credit (BPCR) is on track to deliver a strong (possibly record-high) annual NAV total return (TR) in FY22 on the back of a high investment level in H122, rising interest rates benefiting its floating rate loans, as well as healthy prepayment and make-whole fees from the early loan repayments in recent months. This has allowed BPCR to announce a US$0.045 special dividend, which implies a 12.0% dividend yield for FY22 on the current share price. The above-mentioned fees also provide BPCR with a good income runway for the re-deployment of prepayment proceeds. Since being fully invested in August 2018, BPCR achieved a net NAV TR of c 8% per year.




IPO apocalypse


ESG, moving beyond the box tick

Investment Companies

The case for US capital markets

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free